The United States drug and food Administration(FDA)in the recently announced full recovery of the United States all of Daclizumab formulation, recovery is the FDA to enforce and assist the drug companies(Biogen And AbbVie)to recall all containing Daclizumab medicines.

Daclizumab trade name Zinbryta is a treatment for relapsing multiple sclerosis Multiple Sclerosis, And Daclizumab is a novel fully human source of anti-Tac monoclonal antibody, and its role in IL-2 receptacle α chain. And in this month 2, There are reports of this drug affects the liver and immune problems. In Europe appeared a total of eight cases of severe side effects, and administration of the factory statement that Daclizumab will be in the global recovery and provide only Daclizumab to 2018 4 June 30 to have the clinical needs of the institution.

And in the Macau market, containing Daclizumab formulation is part of hospital medicine(UH), and the inlet makes for Roche, on the Macau market recovery or not invited to the Macau health Bureau query, while the patient to your attending doctor queries.

Translated by Yandex.Translate and Global Translator